Key Challenges in Cell and Gene Therapy Manufacturing

Cell and gene therapy manufacturing presents distinct challenges compared to traditional pharmaceutical production. The use of living starting materials, open processing steps, and viral vectors introduces risks that cannot be mitigated solely by terminal sterilization.

Among these, contamination control stands as one of the most critical and closely scrutinized aspects of manufacturing. Ensuring that products remain free from microbial and cross-contamination requires a comprehensive and proactive strategy that integrates facility design, operational discipline, and rigorous Quality Assurance oversight.

At C3i, contamination prevention is built on a comprehensive Contamination Control Strategy (CCS) that defines how risks are identified, mitigated, and continuously monitored. This structured approach addresses both microbial contamination and cross-contamination, ensuring that potential risks are controlled at every stage of production.

By applying risk-based principles, our Quality Assurance teams establish clear control measures, monitor their effectiveness, and identify potential gaps requiring corrective action. This ensures that contamination risks remain continuously managed as processes evolve.

Facility design plays a central role in preventing contamination:

• controlled cleanroom environments,
• directional airflow,
• and defined pressure cascades

help maintain separation between critical manufacturing areas and surrounding environments.

Where viral and non-viral processes coexist, segregation strategies such as:

• dedicated equipment,
• controlled workflows,
• and specialized ventilation systems

reduce the risk of unintended material transfer.

These engineering controls provide the physical foundation necessary to maintain product integrity.

Operational practices further reinforce these safeguards. Personnel are trained and qualified in aseptic technique to ensure consistent handling of sensitive materials. Validated cleaning and disinfection procedures eliminate residual contaminants from equipment and workspaces, while environmental monitoring programs provide continuous oversight of facility conditions. These measures enable early detection of potential contamination and support timely corrective actions when needed.

Material control represents another essential component of contamination prevention. Pharmaceutical-grade materials are prioritized whenever possible to reduce risk. When biological or human-derived materials are required, supplier qualification and traceability help ensure that their quality and safety are fully understood.

Because starting materials often originate from human cells or tissues, their inherent biological variability introduces additional contamination and safety risks that must be carefully controlled. The increasing use of single-use technologies further strengthens contamination control by minimizing equipment reuse and reducing the potential for cross-contamination.

Quality Assurance integrates these elements into a cohesive system supported by:

• documentation,
• risk assessment,
• and continuous performance monitoring.

This structured approach allows manufacturers to demonstrate that contamination risks are understood, controlled, and actively managed. By maintaining a robust Contamination Control Strategy, C3i ensures that manufacturing operations remain compliant with regulatory expectations while safeguarding product integrity.

In cell and gene therapy manufacturing, contamination control is fundamental to ensuring patient safety and product reliability. Through a structured, proactive strategy, C3i maintains the controlled environments required to support the safe, consistent production of advanced therapies.

This article is drawn from material presented during the webinar Navigating Regulatory Expectations for Quality Assurance in Cell and Gene Therapy Manufacturing, presented on February 19th 2026, by C3i’s expert Richard Vaillancourt, PhD (Quality Assurance Director).